Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SNN 
Smith & Nephew SNATS Inc (SNN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: SNN (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $37.43
1 Year Target Price $37.43
| 1 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 24.54% | Avg. Invested days 43 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 16.73B USD | Price to earnings Ratio 34.04 | 1Y Target Price 37.43 |
Price to earnings Ratio 34.04 | 1Y Target Price 37.43 | ||
Volume (30-day avg) 4 | Beta 0.67 | 52 Weeks Range 23.30 - 38.79 | Updated Date 09/13/2025 |
52 Weeks Range 23.30 - 38.79 | Updated Date 09/13/2025 | ||
Dividends yield (FY) 2.02% | Basic EPS (TTM) 1.11 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 8.26% | Operating Margin (TTM) 14.49% |
Management Effectiveness
Return on Assets (TTM) 5.81% | Return on Equity (TTM) 9.14% |
Valuation
Trailing PE 34.04 | Forward PE 14.1 | Enterprise Value 19339252356 | Price to Sales(TTM) 2.81 |
Enterprise Value 19339252356 | Price to Sales(TTM) 2.81 | ||
Enterprise Value to Revenue 3.25 | Enterprise Value to EBITDA 14.55 | Shares Outstanding 434140992 | Shares Floating 865119671 |
Shares Outstanding 434140992 | Shares Floating 865119671 | ||
Percent Insiders 0.03 | Percent Institutions 7.8 |
Upturn AI SWOT
Smith & Nephew SNATS Inc
Company Overview
History and Background
Smith & Nephew was founded in 1856 in Hull, England, by Thomas James Smith. While Smith & Nephew has a US presence through its SNATS Inc. subsidiary, SNATS Inc. itself does not have a separate independent history. The company has evolved from a small pharmacy to a global medical technology company specializing in orthopaedics, advanced wound management, sports medicine, and ENT.
Core Business Areas
- Orthopaedics: Develops and manufactures joint reconstruction systems (hips, knees, shoulders), trauma products (fracture management), and robotics-assisted surgery solutions. Focuses on innovative implant technologies and surgical techniques.
- Advanced Wound Management: Offers a comprehensive portfolio of products for treating chronic and acute wounds, including negative pressure wound therapy, biological therapies, and traditional wound dressings.
- Sports Medicine: Provides arthroscopic enabling technologies, implants and resection devices used in minimally invasive repair of soft tissue injuries of the knee, hip and shoulder, as well as fixation devices used in trauma surgeries.
- ENT: Offers specialized devices and implants for ear, nose, and throat procedures including tonsillectomy and adenoidectomy procedures.
Leadership and Structure
Smith & Nephew is led by a Chief Executive Officer and a senior management team responsible for various business segments and functions. The company operates with a global structure, with regional headquarters and sales offices around the world. SNATS Inc. is a subsidiary operating within the US market under the overall Smith & Nephew corporate structure.
Top Products and Market Share
Key Offerings
- Knee Implants (ORTHOPEDICS): Smith & Nephew offers a wide range of knee implants, including total and partial knee replacement systems. Market share varies regionally, but the company is a significant player in the global knee implant market. Competitors include Zimmer Biomet (ZBH), Stryker (SYK), and Johnson & Johnson (JNJ) (DePuy Synthes).
- ALLEVYNu25ca Life (ADVANCED WOUND MANAGEMENT): A multi-layered dressing with silicone gel adhesive designed for pressure ulcer prevention. The company is a leading supplier of advanced wound care solutions. Competitors include Mu00f6lnlycke Health Care, ConvaTec (CTEC), and 3M (MMM).
- Sports Medicine Joint Repair: Products include arthroscopic solutions for repairing knee, hip, and shoulder soft tissue injuries. Smith+Nephew competes with Stryker (SYK), Arthrex, and DePuy Synthes (JNJ).
Market Dynamics
Industry Overview
The medical technology industry is characterized by innovation, regulation, and increasing demand due to an aging population and rising healthcare costs. The industry is highly competitive with significant R&D spending.
Positioning
Smith & Nephew is positioned as a global medical technology company with a focus on innovation and providing solutions across orthopaedics, advanced wound management, and sports medicine. The company emphasizes its strong relationships with surgeons and healthcare providers.
Total Addressable Market (TAM)
The global medical device market is estimated to be worth hundreds of billions of dollars annually. Smith & Nephew is positioned to capture a significant portion of this TAM through its diverse product portfolio and global presence.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Global presence and distribution network
- Diverse product portfolio
- Focus on innovation and R&D
Weaknesses
- Subject to intense competition
- Regulatory scrutiny
- Exposure to economic fluctuations
- Can be slower to market with new technologies
Opportunities
- Aging population driving demand for medical devices
- Emerging markets with unmet healthcare needs
- Technological advancements in robotics and digital surgery
- Strategic acquisitions to expand product offerings
Threats
- Pricing pressures from healthcare providers and payers
- Increased competition from established and emerging players
- Product liability lawsuits
- Changes in healthcare regulations and policies
Competitors and Market Share
Key Competitors
- ZBH
- SYK
- JNJ
- BSX
- MRK
- ABT
Competitive Landscape
Smith & Nephew competes with larger and smaller players in the medical technology industry. Its advantages include a diverse product portfolio, global presence, and strong brand reputation. Disadvantages include smaller R&D budget compared to larger competitors and some technological lag in areas like robotics.
Major Acquisitions
CartiHeal
- Year: 2022
- Acquisition Price (USD millions): 330
- Strategic Rationale: Strengthen Smith & Nephew's Sports Medicine portfolio with innovative cartilage regeneration technology.
Growth Trajectory and Initiatives
Historical Growth: Refer to Smith & Nephew (SNN) stock data for historical growth trends.
Future Projections: Refer to analyst estimates for Smith & Nephew (SNN) for future growth projections.
Recent Initiatives: Recent initiatives by Smith & Nephew include investing in R&D for new products, expanding its presence in emerging markets, and making strategic acquisitions.
Summary
Smith & Nephew is a global medical technology company with a solid presence in orthopaedics, advanced wound management, and sports medicine. The company benefits from a diversified product line, a good brand reputation, and global reach. Intense competition, regulatory obstacles, and slow adoption of novel technologies are some challenges that Smith & Nephew is currently facing. The company needs to focus on further innovation and efficient capital allocation to sustain growth and improve its competitive position.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (for SNN)
- Analyst Reports (for SNN)
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and analyst estimates, which are subject to change. It is not financial advice, and investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Smith & Nephew SNATS Inc
Exchange NYSE | Headquaters - | ||
IPO Launch date 1999-11-16 | CEO & Director Dr. Deepak S. Nath Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 17000 | Website https://www.smith-nephew.com |
Full time employees 17000 | Website https://www.smith-nephew.com | ||
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.